{"schema_version":"secwatch.filing_event.v1","accession":"0001193125-23-292084","form_type":"8-K","ticker":"COGT","cik":"0001622229","company_name":"Cogent Biosciences, Inc.","filed_at":"2023-12-11T23:59:59+00:00","discovered_at":"2026-05-14T18:03:29.820521+00:00","generated_at":"2026-06-07T14:54:41.442165+00:00","sec_items":["8.01"],"event_type":"other_material","sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"confidence":"high","headline":"Cogent reports positive Phase 2 bezuclastinib data in systemic mastocytosis at ASH 2023","bullets":["SUMMIT Part 1a: 100% of bezuclastinib patients achieved ≥50% reduction in serum tryptase vs 0% on placebo; 100% achieved ≥50% reduction in KIT D816V VAF.","APEX Part 1: 52% ORR per mIWG-MRT-ECNM criteria (56% in TKI-naïve); 75% PPR ORR (86% in TKI-naïve).","Safety: no related cognitive impairment or bleeding events; most AEs low grade and reversible.","SUMMIT Part 2 (registration-directed) to start H1 2024; APEX Part 2 (~65 patients) enrollment on track for end of 2024.","100% of bezuclastinib patients in SUMMIT with measurable baseline mast cell aggregates achieved ≥50% reduction in bone marrow mast cell burden vs 14% placebo."],"urls":{"canonical":"https://secwatch.observer/filing/0001193125-23-292084","json":"https://secwatch.observer/filing/0001193125-23-292084.json","markdown":"https://secwatch.observer/filing/0001193125-23-292084.md","text":"https://secwatch.observer/filing/0001193125-23-292084.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1622229/000119312523292084/0001193125-23-292084-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1622229/000119312523292084/d844329d8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-07T14:54:41.442165+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}